// App-Quantinova.ai

O28 : Biosimilar use in children and young people with juvenile idiopathic arthritis in areal-world setting in the United Kingdom

Researchers

Presenter

  • Diederik De Cock

Principal Investigators

  • Lianne Kearsley-Fleet

  • Eileen Baidam

  • Michael Beresford

  • Helen Foster

  • Taunton Southwood

  • Wendy Thomson

  • Kimme Hyrich

Medical Centers

  • Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UNITED KINGDOM

  • Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS FoundationTrust, Liverpool

  • Institute of Translational Medicine (Child Health, University of Liverpool, Liverpool

  • Newcastle University and Great North Children's Hospital, Newcastle University and Great North Children's Hospital, Newcastle, UNITED KINGDOM

  • School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom

  • Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • Etanercept

  • CHS-0214

  • Infliximab Biosimilar

  • Etanercept biosimilar

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved